Table 3.

Distribution of FCRL3 SNP–169T/C genotype and allele frequencies in healthy Taiwanese controls, RA patients, and RA patients with different clinical manifestations.

Characteristic (n)	Genotype			Minor Allele Frequency	p for Trend	Chi-square	Genotype Analysis (CC vs CT + TT) OR (95% CI)	p	Chi-square	Allele Analysis (C vs T) OR (95% CI)	p
Characteristic (n)	CC	CT	TT	Minor Allele Frequency	p for Trend	Chi-square	Genotype Analysis (CC vs CT + TT) OR (95% CI)	p	Chi-square	Allele Analysis (C vs T) OR (95% CI)	p
RA (670)	115	322	233	0.412	0.844	0.086	0.968 (0.778–1.204)	0.769	0.039	1.015 (0.874–1.178)	0.84
Controls (758)	130	370	258	0.416
Destructive RA (423)	79	211	133	0.436	0.011^*	7.221	1.672 (1.149–2.432)	0.007	6.689	1.423 (1.089–1.859)	0.010
Non-destructive RA (159)	22	68	69	0.352
CCP-positive RA (487)	82	244	161	0.419	0.165	3.417	1.443 (0.978–2.128)	0.065	1.921	1.216 (0.922–1.602)	0.166
CCP-negative RA (137)	22	58	57	0.372
RF-positive RA (531)	90	259	182	0.413	0.836	0.283	1.111 (0.753–1.639)	0.595	0.043	1.029 (0.789–1.346)	0.836
RF-negative RA (139)	25	63	51	0.407
Female RA (577)	91	287	199	0.406	0.615	0.072	0.968 (0.763–1.229)	0.789	0.248	0.960 (0.816–1.129)	0.619
Female controls (628)	107	309	212	0.416
Female destructive RA (367)	67	137	113	0.437	0.002^*	8.358	1.823 (1.214–2.736)	3.8 × 10⁻³	9.568	1.590 (1.185–2.132)	0.002
Female non-destructive RA (134)	14	60	60	0.328
Female CCP-positive RA (417)	66	218	133	0.420	0.049^*	5.517	1.640 (1.085–2.479)	0.019	3.971	1.353 (1.005–1.821)	0.046
Female CCP-negative RA (122)	16	53	53	0.348
Female RF-positive RA (458)	73	232	153	0.416	0.389	1.149	1.256 (0.828–1.906)	0.284	0.719	1.135 (0.847–1.521)	0.397
Female RF-negative RA (119)	16	53	53	0.382

↵* 100,000 permutations. CPP: cyclic citrullinated peptide; RF: rheumatoid factor.